Evidence map›Paper›PMID 35184201›Full record

ArticleThe Journal of infectious diseases2022

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages.

Tommy Nyberg, Katie Harman, Asad Zaidi, Shaun R Seaman, Nick Andrews, Sophie G Nash, Andre Charlett, Jamie Lopez Bernal, Richard Myers, Natalie Groves and 7 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tommy NybergMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9436-0626
Katie HarmanCOVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0003-1387-0200
Asad ZaidiCOVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0002-6420-2539
Shaun R SeamanMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3726-5937
Nick AndrewsImmunisation and Countermeasures Division, UK Health Security Agency, London, United Kingdom.ORCID 0000-0003-2069-2684
Sophie G NashCOVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0002-7717-6982
Andre CharlettNational Infection Service, UK Health Security Agency, London, United Kingdom.ORCID 0000-0001-7154-0432
Jamie Lopez BernalImmunisation and Countermeasures Division, UK Health Security Agency, London, United Kingdom.ORCID 0000-0002-1301-5653
Richard MyersGenomics Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0003-4269-1164
Natalie GrovesGenomics Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0002-3832-3484
Eileen GallagherGenomics Cell, UK Health Security Agency, London, United Kingdom.
Saheer GharbiaGenomics Programme, UK Health Security Agency, London, United Kingdom.ORCID 0000-0003-0206-051X
Meera ChandGenomics Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0001-9697-0340
Simon ThelwallCOVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0002-0434-2724
Daniela De AngelisMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-6619-6112
Gavin DabreraCOVID-19 National Epidemiology Cell, UK Health Security Agency, London, United Kingdom.ORCID 0000-0003-4606-5945
Anne M PresanisMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3078-4427

Funding

Medical Research Council MC_PC_19074Medical Research Council MC_UU_00002/11
6 · The paper itself

Abstract

To investigate if the AY.4.2 sublineage of the SARS-CoV-2 delta variant is associated with hospitalization and mortality risks that differ from non-AY.4.2 delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine health care datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR = 0.85; 95% confidence interval [CI], .77-.94), hospital admission or emergency care attendance (aHR = 0.87; 95% CI, .81-.94), and COVID-19 mortality (aHR = 0.85; 95% CI, .71-1.03). The results indicate that the risks of hospitalization and mortality are similar or lower for AY.4.2 compared to cases with other delta sublineages.

Indexed as

COVID-19SARS-CoV-2HospitalizationHumansRetrospective StudiesAY.4.2COVID-19hospitalizationmortalitySARS-CoV-2VUI-21OCT-01

Identifiers

PMID35184201
PMCPMC8903446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.